Next generation skin sensitisation testing by Senzagen

Malmborg Hager A., Johansson H., Lindstedt M., Borrebaeck CA.

 Summary:

DNA is the software that predicts human phenotypes. Genomics utilises DNA as such a piece of software, which in several recent applications has been demonstrated to be able to predict a number of biological features, enabling anything from face recognition to vaccine development. The tremendous information content, harboured in the DNA, should be harnessed in tests of cosmetic ingredients and formulations, to get a complete insight into what is happening in the body when these types of products are applied to the human skin. This type of complex information gives a holistic view of a human condition that many of us are familiar with, such as e.g. allergic contact dermatitis, and has the potential not only to classify chemicals used in cosmetics but also to determine the magnitude to which a chemical affects the human body (the potency).

This distinguishes genomics from most other test principles, where in many cases only one or two markers are being monitored, such as DC activation markers (CD86, CD54), genes involved in cytoprotective responses to oxidative stress or electrophilic compounds (Nrf2, Keap1), or proinflammatory cytokines, (e.g. IL18).

Link to pdf doc: GARD_in_sixsteps_LIVe_SenzaGen_2018-07

SenzaGen signs distribution agreement with the French test laboratory Eurosafe

July 16, 2018 PR_SenzaGen distribution agreement with Eurosafe.180716

SenzaGen (Nasdaq First North: SENZA) and the French CRO Eurosafe announce today that they have entered into a distribution agreement regarding GARDskin™ and GARDpotency™.

The GARD™ portfolio consists of animal-free tests developed by SenzaGen for safety assessment of chemical ingredients and mixtures. The agreement confirms the interest in SenzaGen’s technology and opens up new business opportunities on the important French market. Under the agreement, Eurosafe will market and sell GARDskin™ and GARDpotency™ to its clients.

For more information, please contact

Anki Malmborg Hager,
CEO, SenzaGen AB
Email: anki.malmborg.hager@senzagen.com
Telephone: +46 768 284 822